Funding: These guidelines were developed independently through funding from Victorian Integrated Cancer Services. The Western and Central Melbourne Integrated Cancer Service (WCMICS), one of three metropolitan and five regional Integrated Cancer Services funded by the Victorian Department of Human Services to implement the Victorian Government's Cancer Services Framework across Victoria, administered this funding.
Use of risk stratification to guide ambulatory management of neutropenic fever
Article first published online: 28 JAN 2011
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians
Internal Medicine Journal
Special Issue: Australian consensus guidelines for the management of neutropenic fever in adult cancer patients
Volume 41, Issue 1b, pages 82–89, January 2011
How to Cite
Worth, L. J., Lingaratnam, S., Taylor, A., Hayward, A. M., Morrissey, S., Cooney, J., Bastick, P. A., Eek, R. W., Wei, A. and Thursky, K. A. (2011), Use of risk stratification to guide ambulatory management of neutropenic fever. Internal Medicine Journal, 41: 82–89. doi: 10.1111/j.1445-5994.2010.02339.x
Conflict of interest: The following working group members are consultants or advisory committee members or receive honoraria, fees for service, or travel assistance (independent of research-related meetings) form; or have research or other associations with the organizations listed: Ian Davis – Novartis, Pfizer, GlaxoSmithKline, Schering-Plough; Andrew Grigg – Amgen, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Schering Plough, Sue Kirsa – Roche, Schering Plough, Amgen, Hospira, Alphapharm; Senthil Lingaratnam – Victorian Integrated Cancer Services; Orla Morrissey – Gilead, Merck Sharp & Dohme, Orphan, Pfizer, Schering Plough; William Renwick – Roche; Monica Slavin – Gilead, Merck Sharp & Dohme, Pfizer, Schering Plough; Brian Stein – Merck Serono; Constantine Tam – GSK, Roche; Karin Thursky – Gilead, Merck Sharp & Dohme, Pfizer, Schering Plough; Andrew Wei – Celgene, Hospira, Novartis.
- Issue published online: 28 JAN 2011
- Article first published online: 28 JAN 2011
- Received 30 August 2010; accepted 31 August 2010.
This article has been cited by:
- 1A new prognostic model for chemotherapy-induced febrile neutropenia, International Journal of Clinical Oncology, 2016, 21, 1, 46, , , , ,
- 2Can mortality of cancer patients with fever and neutropenia be improved?, Current Opinion in Infectious Diseases, 2015, 28, 6, 505, ,
- 3A proposal for a simplified MASCC score, Supportive Care in Cancer, 2013, 21, 4, 915, ,
- 5Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies, Hematology, 2013, 2013, 1, 414,
- 8Net reclassification improvement: a link between statistics and clinical practice, European Journal of Epidemiology, 2013, 28, 1, 21, ,
- 9Clinically Relevant Measures of Fit? A Note of Caution, American Journal of Epidemiology, 2012, 176, 6, 488,
- 10Re: "Problems With Risk Reclassification Methods for Evaluating Prediction Models", American Journal of Epidemiology, 2011, 174, 7, 874,
- You have free access to this content11